Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Research Article Volume 3 Issue 4

An Update on Aetiopathogenesis and Management of Japanese Encephalitis - A Systematic Review

Kulvinder Kochar Kaur1*, Gautam Allahbadia2 and Mandeep Singh3*

1Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Punjab, India
2Rotunda-A Centre for Human Reproduction, Mumbai, India
3Consultant Neurologist, Swami Satyanand Hospital, Jalandhar, Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Punjab, India.

Received: November 06, 2018; Published: March 24, 2020



  A systematic review was carried out regarding the aetiopathogenesis of Japanese encephalitis along with its management using the pubmed search engine for MeSH terms like Japanese encephalitis, Japanese encephalitis virus; epidemiology; treatment ;vaccines for this systematic review from 1955 till date in 2020. We found a total of 6817 articles out of which we selected 50 articles for this systematic review. No meta-analysis was done. JEV and West Nile virus (WNV) are the most common encephalitic Flaviviruses. The family of Flaviviridae contains >70 members which were initially separated on the basis of cross reactivity of the antibodies they induce. Initial evaluations with polyclonal antisera into 7 subgroups, known as serocomplexes. Members of the same serocomplex are defined by the cross neutralization of the antibodies they induce. JEV and WNV belong to the same JEV serocomplex in combination with other viruses like Murray Valley encephalitic virus (MVEV), St Louis encephalitic virus (SLEV), as well as Usutu virus (USUV). Both JEV and WNV share certain ecological similarities since they maintain an enzootic transmission cycle with various bird families as natural reservoirs and mosquitoes of the Culex species as main vectors. Nonspecific treatment is available till date despite the global importance and severity of presentation causing mortality or lot of life long sequelae. Here we have tried to detail how to manage a case of acute encephalitis having a differential diagnosis of Japanese encephalitis once out of the critical stage. Role of innovative drugs that are investigational as well as orlistat is elaborated as well as different vaccines and cross reactivity of JEV antibodies with Zika virus, WNV as well as cost effectiveness of JE vaccine.

Keywords: Flaviviruses; Japanese Encephalitis; JEV; Acute Encephalitis; MRI; Orlistat



  1. Turtle L and Solomon T. “Japanese encephalitis -the prospects for new treatments”. Nature Review Neurology 14.55 (2018): 298-313. 
  2. Calisher CH., et al. “Antigenic relationships between Flaviviruses as determined by cross-neutralization tests with polyclonal antisera”. Journal of General Virology 70 (1989): 37-43. 
  3. Van den Hurk AE., et al. “Ecology and geographical expression of Japanese encephalitis virus”. Annual Review of Entomology 54 (2009): 17-35. 
  4. Chancey C., et al. “The global ecology and epidemiology of West Nile virus”. BioMed Research International (2015): 1-20. 
  5. Ladreyt H., et al. “How central is the domestic pig in the epidemiological cycle of Japanese encephalitis virus? A review of scientific evidence and implication for disease control”. Viruses 11 (2019): 949. 
  6. Bruescher EL., et al. “Ecologic studies of Japanese encephalitis virus in Japan, IV, Avian infection”. American Society of Tropical Medicine and Hygiene 8 (1959): 678-688. 
  7. Monasteri M., et al. “A four year survey (2011-2014) of West Nile virus infection in humans, mosquitoes and birds, including the 2012 meningoencephalitis outbreak in Tunisia”. Emerging Microbes and Infections 7 (2018): 28. 
  8. Cleton NB., et al. “Age related susceptibility to Japanese encephalitis virus in domestic ducklings and chick”. American Society of Tropical Medicine and Hygiene 90 (2014): 242-246. 
  9. Horwood PF., et al. “Aetiology of acute meningoencephalitis in Cambodian children 2010-2013”. Emerging Microbes and Infections 6 (2017): e35. 
  10. Solomon T. “Control of Japanese encephalitis -Within our grasp”. The New England Journal of Medicine 355 (2006): 869-871. 
  11. Hills SL., et al. “Disability from Japanese encephalitis in Cambodia and Vietnam”. Journal of Tropical Pediatrics's 57 (2011): 241-244. 
  12. Campbell G., et al. “Estimated global incidence of Japanese encephalitis”. Bulletin of the World Health Organization 89 (2011): 766-774. 
  13. Auerwald H., et al. “Serological evidence for Japanese encephalitis and West Nile virus infections in Domestic Birds in Cambodia”. Frontier Veterinary Science 7 (2020): 15. 
  14. Keng LT and Chang LY. “Japanese encephalitis”. CMAJ 190.21 (2018): E-657-E657. 
  15. Yun SL and Lee YM. “Japanese encephalitis: The virus and vaccines”. Human Vaccines and Immunotherapeutics 10 (2014): 263-279. 
  16. Dung NM., et al. “An evaluation of the usefulness of neuroimaging for the diagnosis of Japanese encephalitis”. Journal of Neurology 256 (2009): 2052-2060. 
  17. Kalita J and Misra UK. “Comparison of CT scan and MRI findings in the diagnosis of Japanese encephalitis”. Journal of the Neurological Sciences 174 (2000): 3-8.
  18. Hegde AN., et al. “Differential diagnosis of bilateral abnormalies of the basal ganglia and thalamus”. Radiographics 31 (2011): 5-30. 
  19. Diagana M., et al. “Japanese encephalitis revisited”. Journal of the Neurological Sciences 262 (2007): 165-170. 
  20. Qi LH., et al. “Japanese encephalitis following liver transplantation-a case report”. World Journal of Clinical Cases 8 (2020): 337-342. 
  21. Kumar R. “Understanding and managing acute encephalitis [version 1 peer review:2 approved]”. F1000 Research 60 (2020): 1-10. 
  22. Hoke CH., et al. “Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus”. Journal of Infection Disease 165.4 (1992): 631-637. 
  23. Bergmann M., et al. “Acyclovir resistance in herpes simplex virus type I encephalitis: a case report”. Journal of Neurovirology 23.2 (2017): 335-337.
  24. Tunkel AR., et al. “The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America”. Current Infectious Disease 47.3 (2008): 303-327.
  25. Tunkel AR. “Double-blind Placebo-controlled Trial of Pleconaril in Infants with Enteroviral Meningitis”. Current Infectious Disease Reports 6.4 (2004): 295-296.
  26. Solomon T., et al. “Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial”. Lancet 361.9360 (2003): 821-826.
  27. Kumar R., et al. “Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India”. Current Infectious Disease 48.4 (2009): 400-406.
  28. VN., et al. “Natural chemical entities from Arisaemia Genus might be a promising break through against Japanese encephalitis virus infection: A molecular docking and dynamics approach”. Journal of Biomolecular Structure and Dynamics (2020): 1-25.
  29. Kant K., et al. “Computational identification of natural product leads that inhibit mast cell chymase: an exclusive plausible treatment for Japanese encephalitis”. Journal of Biomolecular Structure and Dynamics (2020): 1-10.
  30. Weaver SC and Reisen WK. “Present and future arboviral threats”. Antivirus Research 85 (2010): 328-345. 
  31. King AM., et al. “Virus Taxonomy: IXth Report of the International Committee on Taxonomy of viruses”. San Diego, CA 9(2012). 
  32. Smith DR. “Waiting in the wings: The potential of mosquito transmitted flavivirus to emerge”. Critical Reviews in Microbiology 43 (2017): 1-18. 
  33. Schmaljohn AL and McClain D. In Medical Microbiology (ed. Baron S) (1996). 
  34. Andrew MQK., et al. “Virus Taxonomy Classification and Nomenclature of Viruses” (2012). 
  35. Martin-Acebes MA., et al. “Lipids and flaviviruses, present and future perspectives for the control of dengue, Zika and West Nile viruses”. Progress in Lipid Research 64 (2016): 123-137. 
  36. Heaton NS and Randall G. “Dengue Virus induced autophagy regulates lipid metabolism”. Cell Host Microbes 8 (2010): 422-432. 
  37. Perrera R., et al. “Dengue Virus infection perturbs lipid homeostasis in infected mosquito cells”. PLoS Pathogens 8 (2012): e1002584. 
  38. Samsa MM., et al. “Dengue Virus capsid protein usurps lipid droplets for viral particle formation”. PLoS Pathogens 5 (2009): e1000632. 
  39. Wakil SJ. “Fatty acid synthase, a proficient multifunctional enzyme”. Biochemistry 28 (1989): 4523-4530.
  40. Heck AM., et al. “Orlistat, a new lipase inhibitor for the management of obesity”. Pharmacotherapy 20 (2000): 270-279. 
  41. Kulvinder Kochar Kaur., et al. “An update on a etiopathogenesis and pathogenesis of obesity”. Obesity and Control Therapies 3. 1 (2016): 1-17. 
  42. Rahman MT., et al. “Fatty acid synthase is a potential therapeutic target in estrogen receptor/progesterone receptor positive endometrioid endometrial cancer”. Oncology 84 (2013): 166-173. 
  43. Menendez JA., et al. “Antitumoral actions of the anti-obesity drug- Orlistat, (Xenical TM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3 mediated transcriptional regression of Her2/neu (erbB2) oncogene”. Annuals of Oncology 16 (2005): 1253-1567.
  44. Wright C., et al. “Anti-Tumorigenic Potential of a novel Orlistat-AICAR Combination in Prostate Cancer Cells”. Journal of Cell Biochemistry 118 (2017): 3834-3845. 
  45. Chuang HY., et al. “Antitumor effect of Orlistat, a fatty acid synthase inhibitor, is via activation of caspase3 on human colorectal carcinoma bearing animal”. Biomed Pharmacotherapy 65 (2011): 286-292. 
  46. Hitakarun A., et al. “Evaluation of the antiviral activity of Orlistat (tetra hydrolipstatin), against Dengue Virus, Japanese encephalitis virus, Zika virus, chikungunya virus”. Scientific Reports 10 (202): 1499. 
  47. He X., et al. “The effect of Japanese encephalitis Virus Antibodies on Zika virus infection”. Medical Microbiology and Immunology (2020). 
  48. Kaufusi PH., et al. “Selective reactivity of Anti- Japanese encephalitis Virus, NS4B Antibody towards Different Flaviviruses”. Viruses (2020): pii:E212.
  49. Vodicka E., et al. “Japanese encephalitis Vaccination in the Philippines: A cost effectiveness analysis comparing alternative delivery strategies”. Vaccine (2020): pii:S0264-410X (20) 30205-X. 
  50. Yang H., et al. “A novel amino acid site closely associated with the neurovirulence of live, attenuated Japanese encephalitis Vaccine (SA14-14-2 strain)”. Vaccine 7 (2020): 2636-2642.


Citation: Kulvinder Kochar Kaur., et al.“An Update on Aetiopathogenesis and Management of Japanese Encephalitis - A Systematic Review". Acta Scientific Microbiology 3.4 (2020): 176-184.

Member In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 25, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US